The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
المخرجات
Research outputs
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
International Journal of Analytical Chemistry · vol. 2026 (1) · 4376722-4376722
Dasatinib, a therapy for chronic myeloid leukemia, suffers from poor bioavailability. Self‐microemulsifying drug delivery systems (SMEDDSs) are used to improve its dissolution. This study aimed to develop and validate a novel reverse‐phase high‐performance liquid chromatography (RP‐HPLC) method for quantifying dasatinib in SMEDDS formulations. The RP‐HPLC method utilized a mobile phase of methanol and 0.1% trifluoroacetic acid (55:45, v/v) and identified a peak wavelength for dasatinib at 324 nm. SMEDDS formulations comprised Capryol 90, Transcutol HP, and Tween 40. The method was validated according to ICH guidelines, demonstrating excellent linearity ( R 2 = 0.9993), accuracy (recovery between 98% and 101%), and precision (relative standard deviation of 0.73%). It also showed stability and reliability with limits of detection and quantification of 0.17 and 0.50 µg/mL, respectively. This RP‐HPLC method meets all validation criteria and provides a robust, cost‐effective tool for analyzing dasatinib in SMEDDS formulations.
dasatinibself-microemulsifying drug delivery systemRP-HPLC method developmentmethod validation
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.
International Journal of Clinical and Medical Research · vol. 3 (1) · 34-39
Arthritis represents a heterogeneous group of inflammatory and degenerative joint disorders characterized by persistent inflammation, oxidative stress, cartilage degradation, synovial dysfunction and progressive impairment of joint integrity. Rheumatoid Arthritis (RA) and Osteoarthritis (OA), although distinct in etiology, share several pathological mechanisms involving excessive production of Reactive Oxygen Species (ROS), mitochondrial dysfunction, inflammatory cytokine activation and dysregulation of redox-sensitive signaling pathways [1-4]. The nuclear factor erythroid 2-related factor 2 (Nrf2)-Kelch-like ECH-associated protein 1 (Keap1) pathway is a major endogenous defense mechanism responsible for maintaining cellular redox homeostasis. Under basal conditions, Keap1 promotes Nrf2 degradation; however, oxidative or electrophilic stress disrupts this interaction, allowing Nrf2 to accumulate and translocate into the nucleus, where it activates antioxidant response element (ARE)-dependent genes, including heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1) and glutathione-related enzymes [5,6]. Increasing evidence indicates that impaired or insufficient Nrf2 activity contributes to persistent oxidative stress and inflammation in arthritic joints [1,7]. Nrf2 also interacts with major inflammatory pathways, particularly nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK) and NLRP3 inflammasome signaling [8]. Nanotechnology offers an opportunity to improve the delivery, stability, bioavailability and tissue targeting of therapeutic agents capable of modulating redox and inflammatory pathways. Among different nanomaterials, silver nanoparticles (AgNPs) have attracted considerable interest because of their antimicrobial, anti-inflammatory, antioxidant and immunomodulatory properties [9-11]. Experimental studies have demonstrated that AgNPs can reduce inflammatory cytokines, regulate NF-κB and MAPK signaling, influence macrophage polarization and alleviate inflammatory tissue injury [9,10]. In experimental RA, targeted folic-acid-modified AgNPs have demonstrated the ability to interact with inflammatory macrophages, promote macrophage apoptosis and repolarization and reduce disease severity [12]. Nevertheless, the relationship between AgNP exposure, oxidative signaling and Nrf2-Keap1 activation is complex and excessive nanoparticle-induced oxidative stress may also produce adverse biological effects. This review examines the role of the Nrf2-Keap1 pathway in arthritis, evaluates nanoparticle-based strategies for modulating redox and inflammatory mechanisms and critically discusses the therapeutic potential and safety considerations of AgNPs. Particular emphasis is placed on the potential intersection between AgNP-mediated redox regulation, Nrf2-Keap1 signaling, NF-κB inhibition, macrophage polarization and joint protection.
Pea protein is gaining global attention as a sustainable, plant-based alternative to animal proteins due to its lower environmental impact. However, conventional thermal processing methods can degrade its functional and nutritional properties. This review explores sustainable non-thermal approaches for pea protein processing, focusing on pre-treatment, extraction, and modification. Ultrasonication is the most effective extraction technique and offers higher protein content (82.76 to 85.76%) compared to alkaline, air classification, and enzymatic methods. For protein modification, enzymatic treatment proves most effective, enhancing digestibility by 20.86 to 22.50% and solubility by 64.28 to 66.55%, while preserving structural integrity, compared to other non-thermal techniques. We critically assess the impact of these techniques on protein conformation, allergenicity reduction, and bioavailability and discuss their applications in food formulations and plant-based alternatives. Despite technological advances, significant research gaps remain in understanding molecular structural changes and challenges in industrial scalability. Future studies should focus on scaling processing methods.
pea proteinnon-thermal processingsonicationprotein extraction
Drug Development and Industrial Pharmacy · vol. 51 (8) · 930-942
PURPOSE: To address the challenges of frequent glipizide dosing, including its variable bioa-vailability and gastrointestinal side effects, this study developed and evaluated mucoadhesive buccal films using natural proteins (albumin, gelatin, casein) combined with HPMC E15 to achieve sustained drug delivery. METHODS: Nine formulations (F1-F9) were prepared using solvent casting technique and sys-tematically characterized. Comprehensive evaluations included: (1) drug-polymer compatibil-ity studies (FT-IR, DSC), (2) physicochemical characterization (thickness, weight uniformity, swelling index, moisture content, folding endurance, surface pH), (3) ex-vivo permeation studies through sheep buccal mucosa, and (4) stability assessments to determine film longevi-ty. RESULTS: Compatibility studies utilizing FT-IR and DSC confirmed no significant incompati-bility between glipizide and the excipients. Some of the important physicochemical character-istics recorded for different formulations were surface pH (6.6 - 6.8), folding endurance (72 - 184), moisture content (5.66 - 12.54%), thickness (0.171 - 0.236 mm), weight (0.150 - 0.238 mg), and swelling index (15.8% after 1 hour to 86.6% after 5 hours). Furthermore, neg-ligible variation was observed in these characteristics when stability studies were conducted after 3 months. The ex-vivo permeation studies demonstrated a sustained release of glipizide over 8 hours, with release percentages ranging from 80.94% to 90%. Formulation F6, which achieved an 8-hour release of 89.29%, was identified as optimal. Kinetic analysis revealed zero-order release kinetics for all formulations. CONCLUSION: The developed mucoadhesive buccal films exhibited excellent sustained-release properties, representing a significant improvement over conventional dosage forms. This in-novative delivery system shows strong potential for enhancing diabetes management through improved bioavailability and patient compliance, while minimizing gastrointestinal side effects.
mucoadhesive buccal filmsglipizidesustained drug releasenatural proteins
Environmental Pollutants and Bioavailability · vol. 37 (1)
This study assessed the effect of thiamethoxam on the Nile tilapia (Oreochromis niloticus) under subacute and chronic exposure. The study focused on biochemical markers, genetic damage, pesticide residue levels in fish flesh, and histopathological changes in fish exposed to different concentrations of thiamethoxam (25, 50) for 30 days and (100, 250 mg/L) for 4 days. The study found that prolonged exposure to high doses of thiamethoxam (50 mg/L for 30 days) had significant negative effects on fish health. This exposure led to increased levels of urea and ALT in the blood, indicating potential damage to the kidneys and liver. Additionally, thiamethoxam caused oxidative stress, as evidenced by elevated levels of MDA and upregulated TLR2 gene expression. Thiamethoxam also negatively impacted the fish’s antioxidant defense system. It significantly reduced the expression of key antioxidant genes like ghrelin and catalase, particularly at 250 mg/L for 4 days. The total antioxidant capacity (TAC) and superoxide dismutase (SOD) levels remained relatively stable, except for slight decreases at the highest dose. Thiamethoxam residues were detected in the muscle tissue of fish, with the highest levels found in the 250 mg/L for 4 days. Histological examination revealed severe degenerative changes in the gills and liver tissues of the fish exposed to thiamethoxam, with the severity of the damage increasing with the concentration of the pesticide. In conclusion, cautions must be taken when we use neonicotinoids due to its negative feedback impact on Nile Tilapia fish health and consequently affect humans as a final consumer.
Background Theobromine derivatives have emerged as promising anticancer agents, but their therapeutic potential is limited by poor bioavailability. This study investigates a chitosome-based delivery system for a novel theobromine derivative, N -(4-Chlorophenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1 H -purin-1-yl)acetamide ( T-1-PCPA ), to evaluate its anticancer potential. Methods T-1-PCPA -loaded chitosomess ( T-1-PCPA loaded chitosomes) were formulated using the thin film hydration technique. Molecular docking was employed to computationally assess the stability of the T-1-PCPA loaded chitosomes. Experimentally, various physicochemical properties, including particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency, were analyzed. Transmission electron microscopy (TEM) was used to investigate morphological features. In vitro , the cytotoxicity of the T-1-PCPA -PC-CS was evaluated on HCT-116 and A549 cancer cell lines. Further mechanistic studies included cell cycle analysis, apoptosis detection, and cell migration assays were performed. Results The T-1-PCPA loaded chitosomes exhibited good colloidal stability, with well-defined spherical particles averaging 142.6 ± 4.3 nm in size, a zeta potential of +32.4 ± 1.6 mV, and an entrapment efficiency of 89.2 ± 2.1%, indicating efficient drug loading and formulation stability. In vitro cytotoxicity assays revealed significantly enhanced anticancer activity, with IC 50 values of 8.05 ± 0.06 μg/mL for HCT-116 and 9.55 ± 0.15 μg/mL for A549 cells—substantially lower than those of free T-1-PCPA and blank formulations. Flow cytometric cell cycle analysis demonstrated arrest at G0-G1 and S phases, while apoptosis analysis revealed a significant increase in total apoptosis (39.55%) in treated HCT-116 cells. Cell migration assays showed a 63.4% reduction in migration compared to control, supporting the formulation's anti-migratory potential. Conclusion T-1-PCPA -loaded chitosomes system shows strong potential as a targeted anticancer nanotherapy, demonstrating enhanced cytotoxicity, apoptosis induction, cell cycle arrest, and anti-migratory activity. With high drug loading, stability, and selectivity toward cancer cells, it addresses key limitations of conventional chemotherapy. These findings warrant further preclinical evaluation for colorectal and lung cancer treatment.
chitosomestheobromine derivativesanticancer drug deliverydrug encapsulation
Toxicology Research · vol. 14 (3) · tfaf034-tfaf034
Abstract Peptic ulcer is a chronic inflammatory disorder affecting large portion of population with difficulty in treatment. Treatment options include inhibition of gastric acid secretion, histamine inhibitors, eradication of Helicobacter pylori infection and tissue lining protection. These therapeutic options have several side effects, low bioavailability and bio-distribution. To further increase bioavailability, control release, stability, site specific delivery and minimize organoleptic side effects of phytochemical, nano-encapsulation is a suitable strategy. Chitosan is a suitable nano-carrier for drug delivery applications in treating peptic ulcer as it is biodegradable, biocompatible, safe and cost-effective. Therefore, Ficus religiosa (FR) leaf extract was loaded into chitosan NPs by ion gelation method for in vivo anti-ulcerative activity in indomethacin-induced peptic ulcer rats. Results showed that FR extract was successfully loaded into CNPs with 84% encapsulation efficiency while the size of empty CNPs was reported to be 620.3 nm as compared to FR-loaded CNPs 811.5 nm. FR-loaded CNPs showed homogeneous size distribution as well greater physical stability. Furthermore, in vivo studies revealed gastro-protective activity of FR-loaded CNPs in reducing the ulcer index (UI) to 0.51 (71.30% inhibition) while indomethacin only untreated rats showed UI 2.99 and insignificant ulcer inhibition 11.02%. Furthermore, FR-loaded CNPs restored gastric pH, healed rat stomach completely without ulcers or hemorrhagic spot and improved antioxidants and blood profiles compared to plant extract or CNPs. These findings confirmed the effective application of FR extract loaded CNPs as anti-ulcer agents and reinforces the importance of nano-encapsulation in improving drug efficacy.
Lung inflammation is a hallmark of several respiratory diseases. Despite the great effectiveness of the synthetic antiinflammatory agents, they cause potential side effects. Polydatin (PD), a natural phytomedicine, has antioxidant and antiinflammatory effects. Its clinical applications are hindered due to poor aqueous solubility, low bioavailability, and rapid metabolism by first-pass effect. Herein, we report the development of a novel chitosan oligosaccharide-coated PD-loaded Poly dl-lactide-co-glycolide nanoparticles (COS-coated PD/PLGA NPs) against a bleomycin-induced pulmonary inflammation in a rat model. The NPs exhibited a small particle size of 188.57 ± 5.68 nm and a high zeta potential of + 18.13 ± 2.75 mV with spherical architecture and sustained release pattern of PD. In vivo studies in bleomycin-induced lung inflammation in a rat model revealed the superior prophylactic activity of COS-coated PD/PLGA NPs over the free drug (PD) as demonstrated by histopathological and immunohistochemical analyses, alongside biochemical assays evaluating oxidative stress biomarkers and inflammatory cytokine levels. Overall, the optimized COS-coated PD/PLGA NPs formulation offers a promising prophylactic platform against many respiratory diseases.
Colloids and Interface Science Communications · vol. 64 · 100814-100814
Lipid nanoparticles (LNPs) represent a groundbreaking advancement in the realms of cosmetics and dermatology, providing advantages over traditional formulations. This paper explores the revolutionary potential of LNPs, particularly Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs), in enhancing cosmetic and dermatological applications. The review highlights the advantages of LNPs, including improved skin penetration, improved bioavailability and controlled release of active ingredients, which together contribute to their superior performance compared to conventional formulations. Notable applications discussed include their roles in acne treatment, anti-aging solutions, wound healing , skin-lightening products, and sunscreens . This study examines the structural features and formulation techniques of LNPs, highlighting biocompatibility , and targeted delivery capabilities. We also explore emerging uses such as genetic medicine and mRNA vaccine delivery, alongside market trends and consumer acceptance. By summarizing recent developments and identifying existing challenges, this paper offers a thorough overview of LNPs for future research in pharmaceutical and cosmetic advancements.
Oral squamous cell carcinoma (OSCC) is a highly malignant and invasive tumor with significant mortality and morbidity. Current treatment modalities such as surgery, radiotherapy, and chemotherapy encounter significant limitations, such as poor targeting, systemic toxicity, and drug resistance. There is an urgent need for novel therapeutic strategies that offer targeted delivery, enhanced efficacy, and reduced side effects. The advent of lipid-based nanoparticles (LNPs) offers a promising tool for OSCC therapy, potentially overcoming the limitations of current therapeutic approaches. LNPs are composed of biodegradable and biocompatible lipids, which minimize the risk of toxicity and adverse effects. LNPs can encapsulate hydrophobic drugs, improving their solubility and stability in the biological environment, thereby enhancing their bioavailability. LNPs demonstrate significantly higher ability to encapsulate lipophilic drugs than other nanoparticle types. LNPs offer excellent storage stability, minimal drug leakage, and controlled drug release, making them highly effective nanoplatforms for the delivery of chemotherapeutic agents. Additionally, LNPs can be modified by complexing them with specific target ligands on their surface. This surface modification allows the active targeting of LNPs to the tumors in addition to the passive targeting mechanism. Furthermore, the PEGylation of LNPs improves their hydrophilicity and enhances their biological half-life by reducing clearance by the reticuloendothelial system. This review aims to discuss current treatment approaches and their limitations, as well as recent advancements in LNPs for better management of OSCC.
oral squamous cell carcinomalipid nanoparticlestargeted drug deliverychemotherapy
International Journal of Nanomedicine · vol. Volume 19 · 7945-7961
Background: Monitoring noncommunicable diseases is regarded as a critical concern that has to be managed in order to avoid a wide variety of complications such as increasing blood lipid levels known as dyslipidemia. Statin drugs, mostly, Rosuvastatin (RSV) was investigated for its effectiveness in treating dyslipidemia. However, reaching the most efficient treatment is essential and improving the effect of RSV is crucial. Therefore, a combination therapy was a good approach for achieving significant benefit. Although RSV is hydrophobic, which would affect its absorption and bioavailability following oral administration, overcoming this obstacle was important. Purpose: To that end, the purpose of the present investigation was to incorporate RSV into certain lipid-based nanocarriers, namely, nanostructured lipid carrier (NLC) prepared with virgin coconut oil (CCO). Methods: The optimized RSV-NLC formula was selected, characterized and examined for its in vitro, kinetic, and stability profiles. Eventually, the formula was investigated for its in vivo hypolipidemic action. Results: The optimized NLC formulation showed a suitable particle size (279.3±5.03 nm) with PDI 0.237 and displayed good entrapment efficiency (75.6±1.9%). Regarding in vitro release, it was efficiently prolonged for 24 h providing 93.7±1.47%. The optimized formula was established to be stable after 3 months storage at two different conditions; 4°C and 25°C. Importantly, including CCO in the development of RSV-NLC could impressively enhance lowering total cholesterol level in obese rat models, which endorse the potential synergistic action between RSV and CCO. Conclusion: The study could elucidate the impact of developing NLC using CCO for improving RSV anti-hyperlipidemic activity.
Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents · vol. 38 (7)
Background: Due to its low water solubility, Rutin, a crystalline medication used to treat a variety of conditions, has a limited rate of dissolution when given in gastrointestinal fluids. The present study planned to formulate and characterize Rutin using mesoporous silica material (SBA-15) as well as to determine the in-vitro dissolution properties. Methods: Rutin was formulated using mesoporous silica material such as SBA-15. Particle size distribution analysis, fourier transform-infrared (FT-IR) spectroscopy, scanning electron microscopy, and X-ray diffraction were used to characterize the compound in the complex. Rutins solubility and in-vitro release characteristics were assessed. Furthermore, the dissolution data (DD) Solver Excel add-in software was used to evaluate several mathematical models to interpret the Rutin dissolution kinetics from the mesoporous materials. Results: Differential scanning calorimetry was used to confirm Rutins amorphous state, which resulted in a significantly higher rate of dissolution than pure crystalline Rutin. The release of the drug from the Rutin/SBA-15 complex was well-simulated by the Weibull model. Notably, the SBA-15 carrier-mediated complex of Rutin exhibited the highest drug loading and dissolution rate, showing promising potential for enhancing Rutin bioavailability. Conclusion: The findings suggested that Rutin/SBA-15 could be easily incorporated into conventional oral pharmaceutical dosage forms such as capsules and therefore can be utilized for treating ailments such as allergies, inflammation, tumors, infections, protozoal diseases, and spasms. To assess the Rutin/SBA-15 complexs in-vivo pharmacokinetic performance and appropriateness for a range of pharmacological actions, more investigation is required.
Quercetin (QtN) displays low systemic bioavailability caused by poor water solubility and instability. Consequently, it exerts limited anticancer action in vivo. One solution to increase the anticancer efficacy of QtN is the use of appropriate functionalized nanocarriers that preferentially target and deliver the drug to the tumor location. Herein, a direct advanced method was designed to develop water-soluble hyaluronic acid (HA)-QtN-conjugated silver nanoparticles (AgNPs). HA-QtN reduced silver nitrate (AgNO3) while acting as a stabilizing agent to produce AgNPs. Further, HA-QtN#AgNPs served as an anchor for folate/folic acid (FA) conjugated with polyethylene glycol (PEG). The resulting PEG-FA-HA-QtN#AgNPs (further abbreviated as PF/HA-QtN#AgNPs) were characterized both in vitro and ex vivo. Physical characterizations included UV-visible (UV-Vis) spectroscopy, Fourier transform infrared (FTIR) spectroscopy, transmission electron microscopy (TEM), particle size (PS) and zeta potential (ZP) measurements, and biopharmaceutical evaluations. The biopharmaceutical evaluations included analyses of the cytotoxic effects on the HeLa and Caco-2 cancer cell lines using the MTT assay; cellular drug intake into cancer cells using flow cytometry and confocal microscopy; and blood compatibility using an automatic hematology analyzer, a diode array spectrophotometer, and an enzyme-linked immunosorbent assay (ELISA). The prepared hybrid delivery nanosystem was hemocompatible and more oncocytotoxic than the free, pure QtN. Therefore, PF/HA-QtN#AgNPs represent a smart nano-based drug delivery system (NDDS) and could be a promising oncotherapeutic option if the data are validated in vivo.